ReviewInternational journal of surgery (London, England)2026
High-voltage electrical pulses for pancreatic cancer treatment in the era of precision medicine.
Review in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanosecond Pulsed Electric Fields (nsPEFs) for Precision Intracellular Oncotherapy: Recent Advances and Emerging Directions.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) presents a significant therapeutic challenge due to its immunosuppressive tumor microenvironment (TME). Emerging evidence supports the efficacy of high-voltage electrical pulses (HVEPs) in PC treatment, leveraging dual benefits of pancreatobiliary duct integrity maintenance and immunogenicity activation.
objectivePubMed, Embase, Cochrane Library, and Web of Science were searched from January 2000 to January 2025. This review synthesizes recent advances in HVEPs for PC treatment, specifically focusing on clinical translation, mechanistic insights, and combinatorial strategies with other modalities. KEY
findingsHVEPs induce immunogenic cell death and reprogram the TME, converting immunologically "cold" tumors to "hot." We also highlight the synergistic potential of combining HVEPs with surgery, chemotherapy, immunotherapy (notably for prolonging immune effects and activating abscopal responses), and nanomaterials (which enhance targeting, reduce toxicity, and augment efficacy). Current research must still address several outstanding issues in device engineering, mechanism exploration, designing new immunotherapy combinations, and developing nanomaterials.
conclusionsFurther exploration of the mechanisms of HVEPs and the development of combination approaches based on HVEPs - particularly with immunotherapy and nanomaterials - holds significant promise for advancing personalized, precise, and systemic management of PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.